Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing.
The biotech stock with a focus on neuroscience has surged more than 84% this year.
Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%.
The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%.
The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.
Persons:
Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li
Organizations:
Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics
Locations:
InVitae, Invitae, Acadia, ImmunoGen